APOA1 and breast cancer: Urine d-dimer, MMP-1, Apolipoprotein A1, Proteinase 3, and Apolipoprotein L1 need to be validated independently and in multi-marker panels in additional cross-sectional and longitudinal cohorts to confirm if they are superior to current FDA-approved markers for BC detection.